Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Common Equity: 2010-2025

Historic Common Equity for BIO-TECHNE (TECH) over the last 16 years, with Sep 2025 value amounting to $2.0 billion.

  • BIO-TECHNE's Common Equity fell 8.08% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year decrease of 8.08%. This contributed to the annual value of $1.9 billion for FY2025, which is 7.25% down from last year.
  • According to the latest figures from Q3 2025, BIO-TECHNE's Common Equity is $2.0 billion, which was up 2.45% from $1.9 billion recorded in Q2 2025.
  • Over the past 5 years, BIO-TECHNE's Common Equity peaked at $2.1 billion during Q3 2024, and registered a low of $1.5 billion during Q1 2021.
  • Over the past 3 years, BIO-TECHNE's median Common Equity value was $2.0 billion (recorded in 2023), while the average stood at $2.0 billion.
  • Its Common Equity has fluctuated over the past 5 years, first increased by 19.88% in 2021, then fell by 8.08% in 2025.
  • Over the past 5 years, BIO-TECHNE's Common Equity (Quarterly) stood at $1.7 billion in 2021, then increased by 7.29% to $1.8 billion in 2022, then climbed by 7.47% to $2.0 billion in 2023, then increased by 5.85% to $2.1 billion in 2024, then fell by 8.08% to $2.0 billion in 2025.
  • Its Common Equity stands at $2.0 billion for Q3 2025, versus $1.9 billion for Q2 2025 and $2.0 billion for Q1 2025.